Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuro3d SA

Division of Evotec SE
www.neuro3d.fr

Latest From Neuro3d SA

Via Pharmaceuticals Inc.

There's a lot of excitement around the new insights that vulnerable plaque, a certain kind of inflammatory plaque, is the culprit in myocardial infarction, but so far, no one has figured out how to treat it. Thomas Quertermous of Stanford has identified inflammatory pathways that contribute to atherosclerosis and Via Pharmaceuticals was formed to develop a drug, already tested extensively in humans, that emanated from his research program.
BioPharmaceutical Platform Technologies

Deals Shaping the Medical Industry (5/07)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Early-Stage Funding: Fewer Start-Ups Raising Cash In '05

Fundraising among biotech firms classified as start-ups by Windhover's Strategic Intelligence Systems was way down in the first quarter of 2005 compared to the same quarter in 2004, perhaps reflecting the growing difficulties of early-stage fundraising as venture capitalists focus on companies with clinical-stage projects.
BioPharmaceutical Business Strategies

Building a Better Drug for Schizophrenia

Start-ups in pursuit of novel targets are capturing the attention of venture capitalists.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Evotec SE
  • Senior Management
  • Charles Woler, MD, CEO
    Hermann Fuder, MD, PhD, VP, Clin. R&D
    Bertrand Lehuu, Bus. Dev. & Licensing
    Cesare Mondadori, PhD, CSO
  • Contact Info
  • Neuro3d SA
    Phone: (33) 389 3691 70
    130, rue de la Mer Rouge
    Mulhouse, F-68200
    France
UsernamePublicRestriction

Register